Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) COO Matthew Maxwell Donley Sells 65,902 Shares

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP) COO Matthew Maxwell Donley sold 65,902 shares of the firm’s stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $8.00, for a total value of $527,216.00. Following the completion of the sale, the chief operating officer now directly owns 739,456 shares of the company’s stock, valued at approximately $5,915,648. This represents a 8.18 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link.

Aurinia Pharmaceuticals Trading Up 1.3 %

Aurinia Pharmaceuticals stock opened at $8.08 on Wednesday. The company has a quick ratio of 5.11, a current ratio of 5.60 and a debt-to-equity ratio of 0.17. Aurinia Pharmaceuticals Inc. has a 52 week low of $4.71 and a 52 week high of $10.67. The company has a market capitalization of $1.16 billion, a price-to-earnings ratio of -53.86 and a beta of 1.22. The stock has a 50-day moving average price of $8.13 and a 200 day moving average price of $7.85.

Institutional Investors Weigh In On Aurinia Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the company. SBI Securities Co. Ltd. acquired a new stake in shares of Aurinia Pharmaceuticals during the fourth quarter worth about $25,000. GF Fund Management CO. LTD. acquired a new stake in shares of Aurinia Pharmaceuticals during the fourth quarter worth about $27,000. Tower Research Capital LLC TRC lifted its holdings in shares of Aurinia Pharmaceuticals by 368.5% during the fourth quarter. Tower Research Capital LLC TRC now owns 3,350 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 2,635 shares during the period. Vermillion & White Wealth Management Group LLC acquired a new stake in shares of Aurinia Pharmaceuticals during the fourth quarter worth about $31,000. Finally, Natixis acquired a new stake in shares of Aurinia Pharmaceuticals during the fourth quarter worth about $49,000. Institutional investors and hedge funds own 36.83% of the company’s stock.

Analyst Ratings Changes

Separately, StockNews.com downgraded Aurinia Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Wednesday, February 19th.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.